Celgene (NASDAQ:CELG) received a $112.00 target price from stock analysts at Cantor Fitzgerald in a research note issued to investors on Monday. The firm currently has a “hold” rating on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price objective points to a potential upside of 5.57% from the stock’s current price.

Several other research analysts have also issued reports on the company. Atlantic Securities raised Celgene from a “neutral” rating to an “overweight” rating in a research report on Friday. Cann reissued a “buy” rating and issued a $166.00 target price on shares of Celgene in a research report on Wednesday, November 22nd. TheStreet downgraded Celgene from a “b-” rating to a “c+” rating in a research note on Friday, November 17th. BMO Capital Markets upped their price target on Celgene from $148.00 to $155.00 and gave the stock an “outperform” rating in a research note on Friday, November 17th. Finally, Canaccord Genuity set a $140.00 price target on Celgene and gave the stock a “buy” rating in a research note on Thursday, November 16th. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating, twenty have issued a buy rating and two have given a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $139.57.

Celgene (NASDAQ CELG) opened at $106.09 on Monday. Celgene has a 52-week low of $94.55 and a 52-week high of $147.17. The stock has a market capitalization of $83,526.45, a P/E ratio of 16.58, a PEG ratio of 0.82 and a beta of 1.78. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.65 and a quick ratio of 3.52.

Celgene (NASDAQ:CELG) last announced its earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.87 by $0.04. Celgene had a return on equity of 63.80% and a net margin of 27.36%. The firm had revenue of $3.29 billion during the quarter, compared to analyst estimates of $3.42 billion. During the same quarter in the prior year, the company earned $1.58 EPS. The business’s revenue was up 10.2% compared to the same quarter last year. research analysts expect that Celgene will post 6.67 earnings per share for the current fiscal year.

In other Celgene news, Director Gilla Kaplan sold 9,250 shares of the firm’s stock in a transaction dated Tuesday, September 12th. The stock was sold at an average price of $141.56, for a total transaction of $1,309,430.00. Following the sale, the director now directly owns 85,551 shares of the company’s stock, valued at $12,110,599.56. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Terrie Curran sold 1,727 shares of the firm’s stock in a transaction dated Monday, September 25th. The shares were sold at an average price of $143.89, for a total value of $248,498.03. Following the sale, the insider now directly owns 3,925 shares in the company, valued at $564,768.25. The disclosure for this sale can be found here. 0.95% of the stock is currently owned by company insiders.

Large investors have recently bought and sold shares of the business. Thompson Davis & CO. Inc. increased its holdings in shares of Celgene by 5.9% in the second quarter. Thompson Davis & CO. Inc. now owns 773 shares of the biopharmaceutical company’s stock worth $100,000 after purchasing an additional 43 shares during the last quarter. Arcadia Investment Management Corp MI grew its position in Celgene by 118.7% in the third quarter. Arcadia Investment Management Corp MI now owns 737 shares of the biopharmaceutical company’s stock worth $107,000 after acquiring an additional 400 shares in the last quarter. Robecosam AG purchased a new position in Celgene in the third quarter worth about $114,000. Guidant Wealth Advisors purchased a new position in Celgene in the third quarter worth about $119,000. Finally, Capital Bank & Trust Co grew its position in Celgene by 166.8% in the third quarter. Capital Bank & Trust Co now owns 827 shares of the biopharmaceutical company’s stock worth $121,000 after acquiring an additional 517 shares in the last quarter. 80.16% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: “Cantor Fitzgerald Analysts Give Celgene (CELG) a $112.00 Price Target” was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another website, it was stolen and reposted in violation of U.S. and international copyright law. The legal version of this report can be accessed at https://www.thecerbatgem.com/2017/12/11/cantor-fitzgerald-analysts-give-celgene-celg-a-112-00-price-target.html.

About Celgene

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Analyst Recommendations for Celgene (NASDAQ:CELG)

Receive News & Stock Ratings for Celgene Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Co. and related stocks with our FREE daily email newsletter.